

Table SI. Basic information on patients with the G719A mutation.

Gender	Age, years	TNM stage	First-line therapy	First-line PFS, months	Gene mutation type	Second-line therapy	Second-line PFS, months	PD type
Female	65	IIB (POR)	Osimertinib	4	G719A	Dacomitinib	10.1	SP
Male	66	IIIB (POR)	Icotinib	11.6	G719A	Dacomitinib	10.3	SP
Female	76	IV	Dacomitinib	7	G719A	Dacomitinib+Anlotinib	5.9	SP
Female	57	IV	Dacomitinib	8.7	G719A	BCP+R→Dacomitinib	15.3	LP
Female	58	IV	Dacomitinib	38.7	G719A	N/A	N/A	N/A
Male	67	IIB (POR)	Erlotinib	7.7	G719A	Dacomitinib	14.8	SP
Female	70	IV	Afatinib	1.2	G719A	BCP	8.5	SP
Female	41	IV	Gefitinib	4.3	G719A	Afatinib+Bevacizumab	24	SP

TNM, tumor-node-metastasis; PD, progressive disease; LP, local progression; SP, slow progression; PFS, progression-free survival; N/A, information not available; BCP, bevacizumab, carboplatin and paclitaxel; R, radiotherapy; POR, postoperative recurrence.

Table SII. Basic information on patients with the L861Q mutation.

Gender	Age, years	TNM Stage	First-line Therapy	First-line PFS, months	Gene mutation type	Second-line therapy	Second-line PFS, months	PD type
Female	78	IV	Afatinib	9.3	L861Q	Dacomitinib	3.3	SP
Female	64	IV	Dacomitinib	22.4	L861Q	Osimertinib	9.1	SP
Female	63	IV	Dacomitinib	15.7	L861Q	Dacomitinib + Anlotinib	2.3	SP
Female	44	IV	Afatinib	16.8	L861Q	Furmonertinib	9.3	SP
Female	65	IIIB (POR)	Dacomitinib	41.8	L861Q	N/A	N/A	N/A
Female	48	IV	Dacomitinib	24.9	L861Q	Dacomitinib + Anlotinib	12.1	SP
Female	57	IB	Dacomitinib	26.7	L861Q	N/A	N/A	N/A
Male	59	IIB (POR)	Afatinib	15.7	L861Q	N/A	N/A	N/A

TNM, tumor-node-metastasis; PD, progressive disease; SP, slow progression; PFS, progression-free survival; N/A, information not available; POR, postoperative recurrence.

Table SIII. Basic information on patients with the S768I mutation.

Gender	Age, years	TNM stage	First-line therapy	First-line PFS, months	Gene mutation type	Second-line therapy	Second-line PFS, months	PD type
Female	54	IV	Afatinib	17.1	G719A+S768I	BCP	5.4	CP
Male	68	IV	Icotinib	3.2	G719A+S768I	Dacomitinib	6.1	SP
Male	53	IV	Icotinib	6.1	G719A+S768I	R+Icotinib	23.9	LP
Female	45	IV	Gefitinib	8.8	G719C+S768I	Afatinib	2.9	SP
Male	72	IV	Cisplatin-pemetrexed chemotherapy	20.6	G719C+S768I	Afatinib	12.2	CP
Female	62	IV	Dacomitinib	15.9	G719C+S768I	Osimertinib	1	SP
Female	72	IV	Dacomitinib	30.2	G719S+S768I	N/A	N/A	N/A
Female	53	IV	Afatinib	11.3	G719S+S768I	Osimertinib	12.5	SP
Female	61	IV	Icotinib	5.8	G719S+S768I	BCP	7.8	CP
Female	41	IV	BCP	4.4	G719S+S768I	Afatinib + Bevacizumab	7.6	SP
Female	68	IV	Afatinib	27.5	G719X+S768I	Dacomitinib+ Bevacizumab	3	SP
Male	55	IV	BCP+Afatinib	13.6	G719X+S768I	BCP+PD-1	10.7	CP
Male	70	IV	Afatinib	44.4	G719X+S768I	N/A	N/A	N/A
Female	67	IV	Afatinib	5.3	G719X+S768I	Osimertinib	8.7	LP
Female	65	IV	Afatinib	6.5	V769L+S768I	Afatinib + Bevacizumab	4.7	SP

TNM, tumor-node-metastasis; PD, progressive disease; LP, local progression; SP, slow progression; CP, clinical progression; PFS, progression-free survival; N/A, information not available; BCP, bevacizumab, carboplatin and paclitaxel; R, radiotherapy; PD-1, programmed cell death protein 1 inhibitor.